The Underestimated Role of the p53 Pathway in Renal Cancer.
RCC
mutated TP53
p53
p53 pathway
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Nov 2022
22 Nov 2022
Historique:
received:
18
10
2022
revised:
10
11
2022
accepted:
18
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
The TP53 tumor suppressor gene is known as the guardian of the genome, playing a pivotal role in controlling genome integrity, and its functions are lost in more than 50% of human tumors due to somatic mutations. This percentage rises to 90% if mutations and alterations in the genes that code for regulators of p53 stability and activity are taken into account. Renal cell carcinoma (RCC) is a clear example of cancer that despite having a wild-type p53 shows poor prognosis because of the high rate of resistance to radiotherapy or chemotherapy, which leads to recurrence, metastasis and death. Remarkably, the fact that p53 is poorly mutated does not mean that it is functionally active, and increasing experimental evidences have demonstrated this. Therefore, RCC represents an extraordinary example of the importance of p53 pathway alterations in therapy resistance. The search for novel molecular biomarkers involved in the pathways that regulate altered p53 in RCC is mandatory for improving early diagnosis, evaluating the prognosis and developing novel potential therapeutic targets for better RCC treatment.
Identifiants
pubmed: 36497215
pii: cancers14235733
doi: 10.3390/cancers14235733
pmc: PMC9736171
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
EMBO J. 2007 Feb 21;26(4):923-34
pubmed: 17268548
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s
pubmed: 17255291
EMBO J. 1998 Jun 15;17(12):3342-50
pubmed: 9628871
Blood. 1994 Oct 15;84(8):2391-411
pubmed: 7919359
IUBMB Life. 2012 Jan;64(1):64-71
pubmed: 22131136
Mol Cell. 2006 May 5;22(3):395-405
pubmed: 16678111
Genes Dev. 2000 Jan 1;14(1):34-44
pubmed: 10640274
Biomolecules. 2020 Feb 15;10(2):
pubmed: 32075247
Annu Rev Med. 2010;61:329-43
pubmed: 20059341
Biomedicines. 2021 Feb 27;9(3):
pubmed: 33673719
Cell. 2006 Nov 17;127(4):775-88
pubmed: 17110336
Drug Resist Updat. 2020 Mar;49:100671
pubmed: 31841768
Cancers (Basel). 2018 Aug 25;10(9):
pubmed: 30149602
J Mol Cell Biol. 2019 Jul 19;11(7):524-530
pubmed: 30925588
Cell. 2005 Jul 1;121(7):1071-83
pubmed: 15989956
Methods Mol Biol. 2013;965:37-61
pubmed: 23296650
Cell. 1997 Feb 7;88(3):323-31
pubmed: 9039259
Cell Cycle. 2011 Mar 15;10(6):932-50
pubmed: 21368573
Nat Rev Cancer. 2009 Oct;9(10):749-58
pubmed: 19776744
Eur Urol. 2008 May;53(5):917-30
pubmed: 18054825
Cold Spring Harb Perspect Med. 2016 Aug 01;6(8):
pubmed: 26801896
Int J Mol Sci. 2017 Oct 18;18(10):
pubmed: 29057791
Cancers (Basel). 2019 May 22;11(5):
pubmed: 31121848
Clin Cancer Res. 2008 Aug 1;14(15):4726-34
pubmed: 18676741
Curr Opin Genet Dev. 2006 Feb;16(1):78-84
pubmed: 16359855
Cell Biosci. 2017 Nov 13;7:62
pubmed: 29158891
Biomedicines. 2022 Jun 06;10(6):
pubmed: 35740352
J Clin Oncol. 2018 Oct 29;:JCO2018792549
pubmed: 30372397
Cell Death Differ. 2014 Sep;21(9):1377-87
pubmed: 24926616
Biochem Pharmacol. 2008 Mar 15;75(6):1302-12
pubmed: 18234154
Front Biosci (Elite Ed). 2010 Jun 01;2(3):1042-53
pubmed: 20515774
Free Radic Biol Med. 2008 May 15;44(10):1833-45
pubmed: 18342637
Cell Death Differ. 2007 Jun;14(6):1106-16
pubmed: 17318220
Cancers (Basel). 2018 Nov 19;10(11):
pubmed: 30463244
Int J Med Sci. 2018 Sep 7;15(13):1443-1448
pubmed: 30443163
Genes Dev. 1998 Sep 15;12(18):2831-41
pubmed: 9744860
J Exp Clin Cancer Res. 2021 Aug 12;40(1):254
pubmed: 34384473
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancers (Basel). 2020 Nov 18;12(11):
pubmed: 33218139
Cell Cycle. 2006 Sep;5(18):2054-6
pubmed: 16969113
Eur Urol. 2022 Jun;81(6):555-558
pubmed: 34980496
Cell Death Differ. 2017 Jun;24(6):1017-1028
pubmed: 28362428
Mol Cancer Ther. 2018 Jul;17(7):1355-1364
pubmed: 29967214
Cell Rep. 2016 Oct 4;17(2):366-373
pubmed: 27705786
J Mol Cell Biol. 2019 Apr 1;11(4):284-292
pubmed: 30500901
Nat Rev Cancer. 2006 Sep;6(9):663-73
pubmed: 16915296
Nat Rev Nephrol. 2020 Mar;16(3):156-172
pubmed: 31636445
J Urol. 1996 Aug;156(2 Pt 1):506-11
pubmed: 8683726
Semin Cancer Biol. 2019 Apr;55:8-15
pubmed: 30055950
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001073
pubmed: 20457559
Cell. 2009 May 1;137(3):413-31
pubmed: 19410540
Front Cell Dev Biol. 2021 Feb 18;9:648808
pubmed: 33681231
Cancer Res. 2022 Feb 1;82(3):362-364
pubmed: 35110395
Clin Cancer Res. 2016 Nov 15;22(22):5582-5591
pubmed: 27702824
Eur Urol. 2019 Jan;75(1):74-84
pubmed: 30243799
Carcinogenesis. 2018 Mar 8;39(3):368-374
pubmed: 29346503
Mol Cancer. 2017 Mar 21;16(1):67
pubmed: 28327152
Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):205-23
pubmed: 18248313
EMBO Rep. 2016 Nov;17(11):1542-1551
pubmed: 27702985
Carcinogenesis. 2014 Mar;35(3):586-96
pubmed: 24336193
Oncotarget. 2014 Sep 15;5(17):7446-57
pubmed: 25277184
Curr Opin Pharmacol. 2006 Aug;6(4):350-4
pubmed: 16690355
J Exp Clin Cancer Res. 2016 Sep 06;35(1):136
pubmed: 27599722
Cancer Res. 2008 Jan 15;68(2):545-52
pubmed: 18199551
Med Sci (Basel). 2018 Oct 08;6(4):
pubmed: 30297644
Pharm Res. 2015 Oct;32(10):3123-36
pubmed: 26021465
Mol Med Rep. 2021 May;23(5):
pubmed: 33649838
Clin Cancer Res. 2006 Jul 1;12(13):3985-92
pubmed: 16818696
Cell. 1997 Aug 22;90(4):595-606
pubmed: 9288740
Carcinogenesis. 2020 Aug 12;41(8):1017-1029
pubmed: 32619002
Curr Pharm Biotechnol. 2007 Dec;8(6):332-6
pubmed: 18289041
Cell Death Dis. 2021 Jan 5;12(1):1
pubmed: 33414393
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Front Oncol. 2019 Nov 05;9:1154
pubmed: 31781486
J Mol Cell Biol. 2020 Sep 1;12(9):674-687
pubmed: 32722796
J Natl Cancer Inst. 2006 Sep 6;98(17):1181-2
pubmed: 16954469
Cell Cycle. 2011 Jun 15;10(12):1912-5
pubmed: 21558803
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Cell Death Differ. 2019 Jan;26(2):199-212
pubmed: 30538286
Onco Targets Ther. 2014 Feb 27;7:365-74
pubmed: 24600236
J Urol. 2010 Feb;183(2):743-51
pubmed: 20022054
J Biol Chem. 2003 Sep 26;278(39):37722-9
pubmed: 12851404
Nat Cell Biol. 2009 Sep;11(9):1135-42
pubmed: 19701195
Cancer Cell. 2006 Dec;10(6):501-14
pubmed: 17157790
Cancers (Basel). 2021 Oct 18;13(20):
pubmed: 34680379
Membranes (Basel). 2022 Feb 09;12(2):
pubmed: 35207121
Cancers (Basel). 2020 Aug 03;12(8):
pubmed: 32756406
Oncogene. 2017 Apr 6;36(14):1965-1977
pubmed: 27841868
J Exp Clin Cancer Res. 2017 Nov 28;36(1):167
pubmed: 29179721
Cancer Res. 2007 Jan 15;67(2):450-4
pubmed: 17234751
Genes Cancer. 2011 Apr;2(4):453-65
pubmed: 21779513
Nat Cell Biol. 1999 May;1(1):20-6
pubmed: 10559859
Urol Oncol. 2019 Sep;37(9):578.e1-578.e10
pubmed: 30948335
Int J Mol Sci. 2020 Dec 17;21(24):
pubmed: 33348923
J Biol Chem. 2002 Jun 21;277(25):22330-7
pubmed: 11950834
J Mol Cell Biol. 2016 Feb;8(1):88-90
pubmed: 26705306
Nat Genet. 1992 Apr;1(1):45-9
pubmed: 1301998
Cell Cycle. 2012 Feb 1;11(3):511-23
pubmed: 22262183
Mol Cell Biol. 1999 Feb;19(2):1202-9
pubmed: 9891054
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a000950
pubmed: 20457558
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Int J Mol Sci. 2020 Apr 03;21(7):
pubmed: 32260198
Cell. 2009 May 15;137(4):609-22
pubmed: 19450511
Mol Oncol. 2019 Jan;13(1):46-60
pubmed: 30430751
Trends Cancer. 2016 Dec;2(12):758-770
pubmed: 28741521
Int J Mol Sci. 2019 Dec 18;21(1):
pubmed: 31861395
Nat Rev Cancer. 2006 Dec;6(12):909-23
pubmed: 17128209
Methods Enzymol. 2006;407:597-612
pubmed: 16757355
Cancer Cell. 2014 Mar 17;25(3):304-17
pubmed: 24651012
Oncotarget. 2018 Apr 17;9(29):20508-20523
pubmed: 29755668
Nat Commun. 2014 Aug 21;5:4706
pubmed: 25144556
J Cancer Res Clin Oncol. 2021 Dec;147(12):3565-3576
pubmed: 34499221